宫颈癌预后与表皮生长因子受体蛋白表达关系  

Expression of EGFR in human cervical carcinoma and clinical outcome

作　　者：王利娟[1] 田园[1] 高积勇[1] 

机构地区：[1]西安交通大学医学院第一医院妇产科,陕西西安710061

出　　处：《中国妇幼健康研究》2006年第4期280-282,共3页Chinese Journal of Woman and Child Health Research

摘　　要：目的探讨宫颈癌患者术后预后情况与表皮生长因子受体蛋白表达的关系。方法42例宫颈癌组织,用免疫组织化学S P法检测表皮生长因子受体EGFR蛋白表达水平。随访5～8年,分析表皮生长因子受体的蛋白表达与各临床相关因素的关系。结果随宫颈癌临床分期升高、癌组织宫颈浸润程度加深,表皮生长因子受体阳性表达率逐渐升高,经统计学检验有显著性差异(P＜0．05)。对42例患者,随访60～90月,表皮生长因子受体阴性组生存时间均数80．00月,5年生存率为83．3%；阳性组生存时间均数78．93月,5年生存率为73．3%。结论检测宫颈癌中表皮生长因子受体的蛋白表达可能对宫颈癌的诊断、治疗及评价预后有重要的临床意义。Objective To investigate relationship between expression of epithelial growth factor receptor （EGFR） and clinical outcomes of patients with cervical carcinoma. Methods The expression levels of EGFR of 42 patients with cervical carcinoma were detected by immunohistochemical SP method, and the patients were followed up till 5 to 8 years after operation for their outcomes such as postoperative 5-year survival rate. Results The expression intensity of EGFR was significantly increased with progression in clinical stage and increase in invasion depth of cervical carcinoma, there were significant differences （ P 〈 0.05 ）. 42 patients were followed up for 60 - 90 months. The mean survival time in negative EFGR expression group was 80.00 months and postoperative 5- year survival rate was 83.3% ; while the mean survival time in positive EFGR expression group was 78.93 months and the postoperative 5-year survival rate was 73.3%. Conclusion The detection for EGFR expression in cervical carcinoma may be of significant importance for diagnosis, treatment and prediction of prognosis of cervical carcinoma.

关 键 词：宫颈癌 表皮生长因子受体 预后 随访 

分 类 号：R737.33[医药卫生—肿瘤]